Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 15Stomach Neoplasms 11Colonic Neoplasms 7Carcinoma, Hepatocellular 7Rectal Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Biliary Tract Neoplasms 3Lymphoma, Large B-Cell, Diffuse 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Adenocarcinoma 2Vipoma 1Somatostatinoma 1Resected Liver Metastases From Colorectal Cancer 1Recurrence 1Quality of Life 1Pathologic Complete Response 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Insulinoma 1Immunotherapy Gastrict Cancer 1HER2-positive Gastric Cancer 1Glucagonoma 1Gastroesophageal Junction Adenocarcinoma 1Gastrinoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

Trastuzumab 1Oxaliplatin 1Fluorouracil 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × HER2-positive Gastric Cancer × Oxaliplatin × Clear all
NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡